{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:33:31Z","timestamp":1790202811141,"version":"4.1.0"},"reference-count":50,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Polish Ministry of Education and Science","award":["SKN\/SP\/603081\/2024"],"award-info":[{"award-number":["SKN\/SP\/603081\/2024"]}]},{"name":"Medical College of Rzeszow University (Rzeszow, Poland)","award":["SKN\/SP\/603081\/2024"],"award-info":[{"award-number":["SKN\/SP\/603081\/2024"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Lumateperone is a novel antipsychotic recently approved for the treatment of schizophrenia. Its unique pharmacological profile includes modulation of serotonergic, dopaminergic, and glutamatergic neurotransmission, differentiating it from other second-generation antipsychotics. This paper explores the pharmacological features and clinical potential of lumateperone across neuropsychiatric conditions. A review of current literature, including pharmacokinetic and pharmacodynamic studies, was conducted. It focused on lumateperone\u2019s mechanism of action and receptor-binding profile, and clinical trials assessing its efficacy and safety in schizophrenia and other psychiatric disorders. Lumateperone demonstrates high affinity for 5-HT2A receptors, moderate affinity for D2 receptors, and low affinity for H1 and 5-HT2C receptors. It acts as a presynaptic D2 agonist and a postsynaptic antagonist, contributing to a favorable side-effect profile with reduced extrapyramidal symptoms. Clinical trials suggest that lumateperone is effective in reducing both positive and negative symptoms of schizophrenia, with minimal metabolic and cardiovascular risks. It is also being explored as an adjunctive therapy for major depressive disorder and bipolar depression. Lumateperone presents a promising therapeutic option for schizophrenia with a novel mechanism of action and a favorable safety profile. Its potential application in other psychiatric conditions warrants further investigation, particularly in treatment-resistant populations.<\/jats:p>","DOI":"10.3390\/ijms252413289","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T06:44:05Z","timestamp":1733899445000},"page":"13289","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Exploring the Pharmacological and Clinical Features of Lumateperone: A Promising Novel Antipsychotic"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5956-7229","authenticated-orcid":false,"given":"Magdalena","family":"Sowa-Ku\u0107ma","sequence":"first","affiliation":[{"name":"Department of Human Physiology, Institute of Medical Sciences, Medical College of Rzesz\u00f3w University, Kopisto 2a, 35-315 Rzesz\u00f3w, Poland"},{"name":"Centre for Innovative Research in Medical and Natural Sciences, Medical College of Rzesz\u00f3w University, Warzywna 1a, 35-310 Rzesz\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8760-7494","authenticated-orcid":false,"given":"Patrycja","family":"Pa\u0144czyszyn-Trzewik","sequence":"additional","affiliation":[{"name":"Department of Human Physiology, Institute of Medical Sciences, Medical College of Rzesz\u00f3w University, Kopisto 2a, 35-315 Rzesz\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafa\u0142 R.","family":"Jaeschke","sequence":"additional","affiliation":[{"name":"Section of Affective Disorders, Department of Psychiatry, Jagiellonian University Medical College, Kopernika 21a, 31-501 Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,11]]},"reference":[{"key":"ref_1","first-page":"617","article-title":"Adverse effects of antipsychotic medications","volume":"81","author":"Muench","year":"2010","journal-title":"Am. Fam. Physician"},{"key":"ref_2","unstructured":"Stahl, S.M. (2021). Targeting Dopamine and Serotonin Receptors for Psychosis, Mood, and Beyond: So-Called \u201cAntipsychotics\u201d. Stahl\u2019s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, Cambridge University Press."},{"key":"ref_3","unstructured":"(2019). CAPLYTA\u2014Lumateperone Capsule, DailyMed\u2014U.S. National Library of Medicine."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40265-020-01271-6","article-title":"Lumateperone: First Approval","volume":"80","author":"Blair","year":"2020","journal-title":"Drugs"},{"key":"ref_5","unstructured":"(2020). Drug Trials Snapshots: CAPLYTA, U.S. Food and Drug Administration."},{"key":"ref_6","unstructured":"(2024, January 31). An Open-Label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder (ClinicalTrials.gov ID: NCT05061719), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05061719?cond=NCT05061719&rank=1."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.biopsych.2015.08.026","article-title":"ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial","volume":"79","author":"Lieberman","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"ref_8","unstructured":"Zorn, S.H. (2021). Chapter Eleven\u2014A review of the pharmacology and clinical profile of lumateperone for the treatment of schizophrenia. Advances in Pharmacology, Academic Press."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Stahl, S.M. (2021). Lumateperone. Stahl\u2019s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, Cambridge University Press.","DOI":"10.1017\/9781108975292"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s41386-018-0251-1","article-title":"Dopamine D2 receptor occupancy of lumateperone (ITI-007): A Positron Emission Tomography Study in patients with schizophrenia","volume":"44","author":"Vanover","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1358\/dot.2018.54.12.2899443","article-title":"Lumateperone: A new treatment approach for neuropsychiatric disorders","volume":"54","author":"Kumar","year":"2018","journal-title":"Drugs Today"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/14656566.2019.1695778","article-title":"An evaluation of lumateperone tosylate for the treatment of schizophrenia","volume":"21","author":"Vyas","year":"2020","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Stahl, S.M. (2021). Stahl\u2019s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, Cambridge University Press.","DOI":"10.1017\/9781108975292"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.euroneuro.2019.06.008","article-title":"Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone","volume":"29","author":"Corponi","year":"2019","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1021\/jm401958n","article-title":"Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders","volume":"57","author":"Li","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1007\/s00213-015-3922-1","article-title":"ITI-007 demonstrates brain occupancy at serotonin 5-HT2A and dopamine D2 receptors and serotonin transporters using positron emission tomography in healthy volunteers","volume":"232","author":"Davis","year":"2015","journal-title":"Psychopharmacology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.mpmed.2016.04.009","article-title":"Pharmacokinetics for the prescriber","volume":"44","author":"He","year":"2016","journal-title":"Medicine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1177\/1060028020936597","article-title":"Lumateperone: A Novel Antipsychotic for Schizophrenia","volume":"55","author":"Greenwood","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1001\/jamapsychiatry.2019.4379","article-title":"Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial","volume":"77","author":"Correll","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00213-014-3704-1","article-title":"Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission","volume":"232","author":"Snyder","year":"2015","journal-title":"Psychopharmacology"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Gomes, F.V., and Grace, A.A. (2021). Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094467"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1017\/S109285291900124X","article-title":"Keeping up with the therapeutic advances in schizophrenia: A review of novel and emerging pharmacological entities","volume":"24","author":"Krogmann","year":"2019","journal-title":"CNS Spectr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40266-019-00668-7","article-title":"Current Agents in Development for Treating Behavioral and Psychological Symptoms Associated with Dementia","volume":"36","author":"Ahmed","year":"2019","journal-title":"Drugs Aging"},{"key":"ref_24","first-page":"9","article-title":"Lumateperone: New Drug or Same Old Drug With a New Dress?","volume":"58","author":"Limandri","year":"2020","journal-title":"J. Psychosoc. Nurs. Ment. Health Serv."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"101976","DOI":"10.1016\/j.ajp.2020.101976","article-title":"2019 FDA approved psychotherapeutic medications","volume":"49","author":"Naguy","year":"2020","journal-title":"Asian J. Psychiatr."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1523\/JNEUROSCI.0984-22.2022","article-title":"Lumateperone Normalizes Pathological Levels of Acute Inflammation through Important Pathways Known to Be Involved in Mood Regulation","volume":"43","author":"Dutheil","year":"2023","journal-title":"J. Neurosci."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"El-Haroun, H., Ewida, S.F., Mohamed, W.M.Y., and Bashandy, M.A. (2021). Atypical Antipsychotic Lumateperone Effects on the Adrenal Gland With Possible Beneficial Effect of Quercetin Co-administration. Front. Physiol., 12.","DOI":"10.3389\/fphys.2021.674550"},{"key":"ref_28","unstructured":"Cooper, D., and Gupta, V. (2024). Lumateperone, StatPearls."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jamapsychiatry.2019.4265","article-title":"The Potential Role of Lumateperone-Something Borrowed? Something New?","volume":"77","author":"Kantrowitz","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1092852916000729","article-title":"Emerging pharmacological therapies in schizophrenia: What\u2019s new, what\u2019s different, what\u2019s next?","volume":"21","author":"Citrome","year":"2016","journal-title":"CNS Spectr."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"20451253211034019","DOI":"10.1177\/20451253211034019","article-title":"The role of lumateperone in the treatment of schizophrenia","volume":"11","author":"Syed","year":"2021","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/14737175.2016.1174577","article-title":"ITI-007 in the treatment of schizophrenia: From novel pharmacology to clinical outcomes","volume":"16","author":"Davis","year":"2016","journal-title":"Expert. Rev. Neurother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00406-023-01654-2","article-title":"A network meta-analysis of efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia","volume":"274","author":"Dong","year":"2024","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S2215-0366(22)00304-2","article-title":"The response of subgroups of patients with schizophrenia to different antipsychotic drugs: A systematic review and meta-analysis","volume":"9","author":"Leucht","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"ref_35","unstructured":"Stahl, S.M. (2021). Prescriber\u2019s Guide: Stahl\u2019s Essential Psychopharmacology, Cambridge University Press. [7th ed.]. Kindle Edition."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1176\/appi.ajp.2021.20091339","article-title":"Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial","volume":"178","author":"Calabrese","year":"2021","journal-title":"Am. J. Psychiatry"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"46804","DOI":"10.4088\/JCP.22m14739","article-title":"The Efficacy of Lumateperone in Patients With Bipolar Depression With Mixed Features","volume":"84","author":"McIntyre","year":"2023","journal-title":"J. Clin. Psychiatry"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/bdi.13310","article-title":"Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: Results from a randomized placebo-controlled clinical trial","volume":"25","author":"Suppes","year":"2023","journal-title":"Bipolar Disord."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Longo, G., Cicolini, A., Orsolini, L., and Volpe, U. (2023). The Novel Antipsychotic Lumateperone (Iti-007) in the Treatment of Schizophrenia: A Systematic Review. Brain Sci., 13.","DOI":"10.3390\/brainsci13121641"},{"key":"ref_40","first-page":"14631","article-title":"Lumateperone for the Treatment of Schizophrenia: Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed","volume":"84","author":"Citrome","year":"2023","journal-title":"J. Clin. Psychiatry"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/YIC.0000000000000371","article-title":"Safety and tolerability of lumateperone for the treatment of schizophrenia: A pooled analysis of late-phase placebo- and active-controlled clinical trials","volume":"36","author":"Kane","year":"2021","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_42","unstructured":"Lumateperone (2023). LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, Lumateperone."},{"key":"ref_43","unstructured":"Lumateperone (2023). Drugs and Lactation Database (LactMed(R)), Lumateperone."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1093\/schbul\/sby018.831","article-title":"Lumateperone (ITI-007) for the treatment of schizophrenia: Placebo-controlled clinical trials and an open-label safety switching study","volume":"44","author":"Vanover","year":"2018","journal-title":"Schizophr. Bull."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1017\/S1092852920001005","article-title":"The Safety and Tolerability of Lumateperone 42 mg for the Treatment of Schizophrenia: A Pooled Analysis of 3 Randomized Placebo-Controlled Trials","volume":"25","author":"Kane","year":"2020","journal-title":"CNS Spectr."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2174\/1871527319666200601145653","article-title":"Evidence on the New Drug Lumateperone (ITI-007) for Psychiatric and Neurological Disorders","volume":"19","author":"Mazza","year":"2020","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_47","first-page":"1","article-title":"Discovery of novel compound promotes neurogenesis by activation of mTOR signaling","volume":"34","author":"Vaidya","year":"2020","journal-title":"FASEB J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1042\/BST20130134","article-title":"Regulation of autophagy by mTOR-dependent and mTOR-independent pathways: Autophagy dysfunction in neurodegenerative diseases and therapeutic application of autophagy enhancers","volume":"41","author":"Sarkar","year":"2013","journal-title":"Biochem. Soc. Trans."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"109442","DOI":"10.1016\/j.cellsig.2019.109442","article-title":"Novel compounds for the modulation of mTOR and autophagy to treat neurodegenerative diseases","volume":"65","year":"2020","journal-title":"Cell Signal."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/14737175.2023.2236795","article-title":"Evaluating lumateperone for its use in treating depressive episodes associated with bipolar I or II disorder in adults","volume":"23","author":"Abuelazm","year":"2023","journal-title":"Expert. Rev. Neurother."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/24\/13289\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:52:19Z","timestamp":1760115139000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/24\/13289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,11]]},"references-count":50,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["ijms252413289"],"URL":"https:\/\/doi.org\/10.3390\/ijms252413289","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,11]]}}}